Emerging as a noteworthy development in the fight against obesity, the drug is generating considerable interest . This treatment combines the action of two established GLP-1 receptor agonists, liraglutide, plus an unique glucose-dependent hormonal component. Initial study results have demonstrated substantial weight reduction in people with a high